Neurocrine Biosciences | Revenu Net



Net Income Changement Date
AbbVie USD -22000000 1.58B 2024-12
Acadia Pharmaceuticals USD 143.74M 110.98M 2024-12
Agios Pharmaceuticals USD -96523000 1.04B 2024-12
ALKERMES USD 367.07M 274.69M 2024-12
Alnylam Pharmaceuticals USD -83763000 27.81M 2024-12
Amgen USD 627M 2.2B 2024-12
Biogen USD 266.7M 121.8M 2024-12
BioMarin Pharmaceutical USD 124.94M 18.86M 2024-12
Cytokinetics USD -150020000 10.52M 2024-12
Dynavax Technologies USD 7.05M 10.54M 2024-12
Exelixis USD 139.86M 21.89M 2025-01
Gilead Sciences USD 1.78B 529M 2024-12
Halozyme Therapeutics USD 137.01M 1000 2024-12
Incyte USD 201.21M 94.76M 2024-12
Intra Cellular Therapies USD -16885000 9.44M 2024-12
Ionis Pharmaceuticals USD -104349000 36.13M 2024-12
Neurocrine Biosciences USD 103.1M 26.7M 2024-12
Pfizer USD 410M 4.06B 2024-12
Prothena USD -57956000 1.04M 2024-12
Regeneron Pharmaceuticals USD 917.7M 422.9M 2024-12
Repligen USD -653000 3.97M 2024-09
Sarepta Therapeutics USD 159.05M 125.44M 2024-12
Teva Pharmaceutical Industries USD -217000000 220M 2024-12
Ultragenyx Pharmaceutical USD -133385000 131K 2024-12
Vertex Pharmaceuticals USD 913M 132.4M 2024-12



Neurocrine Biosciences Revenu Net - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.